Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

James Mullen

Moderated Keynote

Vicarius Pharma

George Golumbeski

Keynote Fireside Chat


Sep 04
Show Filter
7:00am - 8:00am 60 mins
Registration and Networking Breakfast
8:00am - 8:15am 15 mins
Welcome and Opening Remarks
  • Panelist John Westwood - Global Head of Life Sciences, Huron Consulting Group
8:15am - 9:00am 45 mins
Defining your BD Strategy vs. Opportunism - Consistent Corporate Vision

How do you balance your BD strategy while also remaining poised for unanticipated opportunity?

  • Jonathan Lanfear - Global Head, R&D Business Development, Takeda Pharmaceuticals International, Inc
  • Philippe Lopes-Fernandes - Senior Vice President, Global Head of Business Development & Alliance Management, EMD Serono, a division of Merck KGaA, Darmstadt, Germany
  • Phil McGurk - Business Development Lead, Inflammation & Immunology, Pfizer
  • Moderator Helen Ho - Vice President, Corporate Development, Blueprint Medicines
9:00am - 9:30am 30 mins
Moderated Keynote

Listen in as veteran biotech leader Jim Mullen shares insight from his considerable experience in the industry and hear about his new company's focus: helping small biotech do development in Europe

  • James Mullen - Chairman, Vicarius Pharma
  • Moderator Christoph Westphal, MD, PhD - Co-Founder and Partner, Longwood Fund
9:30am - 10:00am 30 mins
Networking Break
10:00am - 10:45am 45 mins
Alternative Capital Sources

Explore the current trends in alternative financing for different stages of biotech investment, and the implications for future financing and development strategy

  • Dee Datta - Chief Business Officer, Xoma
  • Chris Garabedian - Chairman and CEO, Xontogeny
  • Ellie McGuire - Partner, LS Polaris Innovation Fund
  • Ed Zhang - Vice President of Corporate Development, Boston Pharmaceuticals
  • Moderator Christopher de Souza - Director, Broadview Ventures
10:45am - 10:55am 10 mins
Spotlight Focus: Axial Biotherapeutics

Here the story behind the story from Axial CEO David Donabedian, on this 2017 Fierce 15 biotech company, including key takeaways on lessons learned 

  • David Donabedian, PhD - CEO, Co-Founder, Axial Biotherapeutics
10:55am - 11:30am 35 mins
VC Investments: Raising Capital

What are the latest trends in raising capital and how are they impacting biotech investment in the US? How can choosing your partners impact your success? 

  • Panelist David Donabedian, PhD - CEO, Co-Founder, Axial Biotherapeutics
  • Panelist Ellie McGuire - Partner, LS Polaris Innovation Fund
  • Moderator Rich Rieger - Managing Director, Huron Life Sciences
11:30am - 11:40am 10 mins
Spotlight Focus: Turnstone Biologics

Hear from this 2017 Fierce 15 biotech winner's Chief Business Officer on a busy year and gain insight from an inside look at recent key development deals helping to shape the future. 

  • Kris Elverum - Chief Business Officer, Turnstone Biologics
11:40am - 12:15pm 35 mins
Small Biotech & Pharma Partnering

What, when, and where, matters in partnering strategy between small biotech and pharma, discuss the different elements that need to be considered when laying out your long term commercial strategy. 

  • Kris Elverum - Chief Business Officer, Turnstone Biologics
  • Micah Mackison - Senior Vice President, Corporate Development & Strategy, Assembly Biosciences
  • Torsten Mummenbrauer - Senior Vice President, Business Development & Licensing, Hookipa Pharma Inc.
  • Moderator James Kasuboski - Senior Director, Boehringer Ingelheim Venture Fund
12:15pm - 1:15pm 60 mins
Networking Lunch
1:15pm - 1:45pm 30 mins
Creative Deal Structures

What makes a deal creative ? How does necessity lead to invention when thinking outside the box on partnerships, licensing, collaboration and other business development deals in biotech and pharma?

  • Panelist Rodolphe Clerval - CBO, Enterome
  • Panelist Kia Motesharei, PhD - Head of Business Development, Neurology and Immunology, EMD Serono, a division of Merck KGaA
  • Panelist John Quisel - Executive Vice President, Chief Business Officer, Acceleron Pharma
  • Moderator Diala Ezzeddine - CEO, Xiox Therapeutics
1:45pm - 2:15pm 30 mins
When and How to Think Commercial?

How important is an understanding of the commercial environment to a successful transaction? What are the risks of not aligning with partners on market potential and commercial requirements?

  • Panelist Jennifer King - Senior Vice President, Business Development and Alliance Management, Intellia Therapeutics
  • Panelist Susan Graf - Chief Business Officer, Epizyme
  • Panelist Dan Cole - Strategic Marketing and Business Development Director, ERYTECH Pharma
  • Moderator Marc Tomassi - Managing Director, Huron Life Sciences
2:15pm - 2:45pm 30 mins
Keynote Fireside Chat
  • George Golumbeski - President, Grail
  • Moderator Arthur Hiller - CEO, Antyllus Therapeutics
2:45pm - 3:15pm 30 mins
Networking Break
3:15pm - 3:45pm 30 mins
The Impact of Novel Modalities: Deal-Making in the Era of Disruptive Technologies

How might future and emerging tech modalities impact biotech deal-making?

  • Christopher Guiffre - Chief Financial Officer & Chief Operating Officer, Pear Therapeutics
  • Vincent Hennemand - SVP Strategy, Corporate and Business Development, Akili Interactive Labs
  • Moderator David Moller - CSO, Sigilon Therapeutics
3:45pm - 4:15pm 30 mins
Fireside Chat: Academic Partnering - New Models for Mutually Beneficial Collaborations
  • Karen Heidelberger - Partner, Deerfield Management
  • Lesley Solomon - SVP Innovation, Chief Innovation Officer, Dana-Farber Cancer Institute
  • Moderator James Zanewicz - Chief Business Officer, Tulane University School of Medicine
4:15pm - 4:45pm 30 mins
The Future of Deal-Making & Partnerships: 2018 and Beyond

A new twist on future predictions in deal making- including a closer look at disruptive technology and the impact of data on business development deals in biopharma

  • Lawrence Klein - Head of Business Development & Strategy, CRISPR Therapeutics
  • Elizabeth O'Day - CEO & Founder, Olaris Therapeutics
  • Shobha Parthasarathi - Vice President, Strategic Alliances and Business Development, Harrington Discovery Institute
  • Moderator John Hallinan - Chief Business Officer, MassBio
4:45pm - 5:00pm 15 mins
Closing Remarks
  • Rakhshita Dhar - Roche Partnering, Boston Innovation Hub, Roche
5:00pm - 6:00pm 60 mins
Cocktails and Hors d'oeuvres